Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2012 | 07:50pm CEST

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
01:39p MERCK AND : Dealing with cervical cancer vaccination
08/19 ASTRAZENECA : Three new Lynparza indications for new partners AstraZeneca and Me..
08/19 ZAYO : Boothbay Fund Management Upped Zayo Group Hldgs (ZAYO) Position; Merck Sh..
08/19 MERCK AND : FDA expands use of AZ/Mercks Lynparza in the US
08/18DJMERCK AND : Scientists, Out $12 Million, Sue Delaware Over Seizure of Their Stoc..
08/18 MERCK AND : AstraZeneca and Merck & Co., Inc. - LYNPARZA Receives Additional and..
08/18 ASTRAZENECA : and Merck & Co., Inc. - LYNPARZA receives additional FDA approval ..
08/18DJASTRAZENECA : FDA Approves AstraZeneca's Ovarian Cancer Treatment Lynparza Table..
08/18 MEDIVIR : initiates clinical study of birinapant in combination with KEYTRUDA® (..
08/18 BERGENBIO ASA : Results for the Second Quarter and Half year 2017
More news
News from SeekingAlpha
08/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 19, 2017
08/18 Dow 'Safer' Dividend Dogs Hound IBM, Pfizer, & Home Depot Top Gainers Per Aug..
08/18 Top Gain Dow Dogs Are General Electric, IBM, & Pfizer Per Broker August Targe..
08/18 AstraZeneca, Time To Expand The Operation
08/17 My Chemical Romance
Financials ($)
Sales 2017 40 311 M
EBIT 2017 13 703 M
Net income 2017 5 621 M
Debt 2017 4 312 M
Yield 2017 3,06%
P/E ratio 2017 28,97
P/E ratio 2018 18,31
EV / Sales 2017 4,27x
EV / Sales 2018 4,13x
Capitalization 167 705 M
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 70,0 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY4.45%167 705
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554
SANOFI6.97%122 127